In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries
Tobias Manuel Appel,
María Fernanda Mojica,
Elsa De La Cadena,
Christian José Pallares,
Marcela A. Radice,
Paulo Castañeda-Méndez,
Diego A. Jaime-Villalón,
Ana C. Gales,
José M. Munita,
María Virginia Villegas
Affiliations
Tobias Manuel Appel
Grupo de Resistencia Antimicrobiana y Epidemiología Hospitalaria (RAEH), Universidad El Bosque, Bogotá 110121, Colombia
María Fernanda Mojica
Grupo de Resistencia Antimicrobiana y Epidemiología Hospitalaria (RAEH), Universidad El Bosque, Bogotá 110121, Colombia
Elsa De La Cadena
Grupo de Resistencia Antimicrobiana y Epidemiología Hospitalaria (RAEH), Universidad El Bosque, Bogotá 110121, Colombia
Christian José Pallares
Grupo de Resistencia Antimicrobiana y Epidemiología Hospitalaria (RAEH), Universidad El Bosque, Bogotá 110121, Colombia
Marcela A. Radice
Departamento de Microbiología, Inmunología, Biotecnología y Genética, Cátedra de Microbiología, Universidad de Buenos Aires—CONICET, Buenos Aires C1113AAD, Argentina
Paulo Castañeda-Méndez
Department of Infectious Diseases, Hospital Médica Sur, Ciudad de México 14050, Mexico
Diego A. Jaime-Villalón
Department of Infectious Diseases, Hospital San Angel Inn Universidad, Ciudad de México 03330, Mexico
Ana C. Gales
Department of Internal Medicine, Division of Infectious Diseases, Universidade Federal de São Paulo, São Paulo 04039-032, Brazil
José M. Munita
Genomics and Resistant Microbes (GeRM) Group, Millennium Initiative for Collaborative Research On Bacterial Resistance (MICROB-R), Santiago, Región Metropolitana 7650568, Chile
María Virginia Villegas
Grupo de Resistencia Antimicrobiana y Epidemiología Hospitalaria (RAEH), Universidad El Bosque, Bogotá 110121, Colombia
Background: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which has shown activity against isolates producing class A, C and D β-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 and October 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. Results: CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% of Enterobacterales being susceptible. Conclusions: The results of this study underline the potential therapeutic role of CZA in Latin America.
